The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSThree Regulatory News (STEM)

Share Price Information for SThree (STEM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 427.00
Bid: 428.00
Ask: 429.00
Change: -3.00 (-0.70%)
Spread: 1.00 (0.234%)
Open: 421.50
High: 431.00
Low: 421.50
Prev. Close: 427.00
STEM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SThree: FY20 Trading Update

14 Dec 2020 07:00

SThree (STEM) SThree: FY20 Trading Update 14-Dec-2020 / 07:00 GMT/BST Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR), transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.


14 December 2020

 

 

SThree plc

FY20 Trading Update

 

resilient performance WITH MARKET EXPECTATIONS RECENTLY UPGRADED, DRIVEN BY FOCUS ON STEM AND FLEXIBLE WORKING

 

 

SThree plc ("SThree" or the "Group"), the only global pure-play specialist staffing business focused on roles in Science, Technology, Engineering and Mathematics ('STEM'), is pleased to issue a trading update(1) for the financial year ended 30 November 2020.

 

Highlights

 

Group net fees for the full year down 8% YoY, demonstrating resilience against Covid-19's impact and the continued recovery of the underlying business in H2 Continued to take market share in the US, Germany and the Netherlands Full year profit before tax recently upgraded, driven by better than expected Q4 which saw net fees down 7% and stand out performances from the US (up 11%) and Germany (down 3%) Significant sequential improvement of Group performance Q4 vs Q3Contract net fees demonstrating impressive resilience, down 7%. Contract represents 76% of Group net fees (FY 2019: 74%)Permanent net fees also showing resilience down 13% 89% of Group net fees generated from international(2) markets (FY 2019: 87%) Strong balance sheet, with net cash at 30 November 2020 of £50m (30 November 2019: £11m)

 

Mark Dorman, Chief Executive, commented:

 

"FY2020 has been far from what was expected when we entered the year. However, guided by our purpose and our strategy, we have responded thoughtfully and executed well. I am proud to be reporting today on a resilient performance.

 

The crisis has clearly demonstrated, not just for our business but for many businesses, how important it is to be anchored with a clear purpose and a robust strategy. From these foundations our teams have worked incredibly hard to strengthen bonds with clients and candidates whilst quickly adapting their services to suit the dramatic changes in 2020.

 

Our unique position at the centre of STEM and flexible working means we are perfectly poised to capitalise on the opportunities available to us."

 

 

 

 

FY 2020

 

Q4 2020

Q3 2020

Q2 2020

Q1 2020

Net Fees

FY 2020

FY 2019

YOY

 

YOY

YOY

YOY

YOY

 

 

 

 

 

 

 

 

 

Contract

 £235.3m

£254.6m

-7%

 

-6%

-12%

-10%

+2%

Permanent

 £75.6m

£87.8m

-13%

 

-10%

-19%

-17%

-6%

GROUP

 £310.9m

£342.4m

-8%

 

-7%

-14%

-12%

+0%

 

 

 

 

 

 

 

 

 

Management structure

 

 

 

 

 

 

 

 

DACH(3)

£105.8m 

£109.3m

-3%

 

-2%

-9%

-9%

+9%

EMEA Exc DACH(4)

 £117.8m

£141.2m

-16%

 

-20%

-22%

-17%

-6%

USA

 £77.2m

£76.7m

+2%

 

+11%

-3%

-2%

+0%

APAC

 £10.1m

£15.2m

-26%

 

-30%

-27%

-36%

-11%

GROUP

 £310.9m

£342.4m

-8%

 

-7%

-14%

-12%

+0%

 

 

 

 

 

 

 

 

 

Top 5 countries

 

 

 

 

 

 

 

 

Germany

 £96.9m

£101.6m

-4%

 

-3%

-10%

-10%

+7%

Netherlands

 £47.3m

£52.3m

-10%

 

-15%

-13%

-12%

+3%

UK

 £35.2m

£43.9m

-19%

 

-22%

-28%

-19%

-8%

USA

 £77.2m

£76.7m

+2%

 

+11%

-3%

-2%

+0%

Japan

 £5.9m

£7.8m

-25%

 

-25%

-27%

-36%

-11%

ROW(5)

 £48.4m

£60.1m

-17%

 

-19%

-23%

-19%

-7%

GROUP

 £310.9m

£342.4m

-8%

 

-7%

-14%

-12%

+0%

 

 

 

 

 

 

 

 

 

Division Mix

FY 2020

 

 

 

 

 

 

 

Contract

76%

 

 

 

 

 

 

 

Permanent

24%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sector Mix

FY 2020

 

 

 

 

 

 

 

Technology

45%

 

 

 

 

 

 

 

Life Sciences

23%

 

 

 

 

 

 

 

Engineering(6)

22%

 

 

 

 

 

 

 

Banking & Finance

8%

 

 

 

 

 

 

 

Other

2%

 

 

 

 

 

 

 

 

 

Business Performance

 

Group net fees for the year declined 8% with performance across all our markets impacted by declines in aggregate demand as a result of the COVID-19 pandemic. The sequential trend Q4 vs Q3 showed an improvement in performance in net fees across the Group, as the underlying business saw activity levels strengthening.

 

Our Contract-focused business model has shown its greater resilience with net fees down just 7% and now represents 76% of Group net fees. The contractor order book(7) on 30 November has declined 10% YoY, compared to Q3 down 14%. This is a result of increased sales activity levels for the Group along with increased contractor retention levels.

 

Net fees in our DACH region were particularly resilient, down 3% for the year. Its Life Sciences business delivered a strong performance with net fees up 4%. This is in part driven by an exceptional Q1, as well as increased demand in the second half of the year in Clinical Research & Development. Technology was flat for the year with increasing demand for Cyber Security and Data Science skills.

 

EMEA excl DACH saw net fees decline 16% in the year, primarily driven by the UK's performance. The Netherlands, our largest country in the region, saw net fees decline 10%. Our Dutch Engineering business had a strong performance in the year with net fees up 20% and Life Sciences up 6%. We have seen good gains in market share in the Netherlands and Germany(8).

 

The USA is the world's largest STEM staffing market and our business there has demonstrated its strength with net fees up 2% for the year and up 11% in Q4. We also gained market share in the US(8). This region has shown the benefits of investing in the right vertical niches and understanding customer needs. Performance in our Life Sciences business has been particularly strong with net fees growing 16% in the year as we have seen robust demand in the second half of the year in Clinical Operations, Product Development and Quality Assurance. Our Technology business has grown 9% with increased demand in Mobile Applications & Software Development, and Engineering was up 1%. As a key area of focus for the Group we continue to make targeted investments in the region, aligning our resources with the best long-term opportunities.

 

APAC net fees were down 26% in the full year, primarily driven by the more transactional nature of our business in Japan, which is 94% permanent.

 

Group average headcount was down 6% YoY, with period end headcount down 17%. We will continue to invest in line with our previously stated strategy to focus on specific niches within sectors and markets where we can gain valuable market share and cement our position.

 

Liquidity and dividends

 

SThree remains in a strong financial position, with net cash of £50m at 30 November 2020 (30 November 2019: Net cash £11m).

 

As at 30 November 2020 the Group has total accessible liquidity of £155m. This is made up of £50m net cash, a £50m revolving credit facility ("RCF"), a £5m overdraft and £50m from the CCFF (RCF, overdraft and CCFF not drawn down). In addition, SThree has a £20m accordion facility as well as a substantial working capital position reflecting net cash due to SThree for placements already undertaken.

 

We continue to recognise the importance of dividends to our shareholders and are keeping future dividend payments under active review.

 

Analyst conference call

 

SThree is hosting a webinar for analysts and investors today at 0830 BST to discuss the FY Trading Update and to present the Group's STEM staffing market pulse check.

 

If you would like to listen to the webinar please contact SThree@almapr.co.uk

               

The Group plans to issue its results for the financial year ended 30 November 2020 on 25 January 2021.

 

 

(1) All YoY growth rates and business mix percentages in this announcement are expressed at constant currency and exclude Australia, which we exited in Q4 2020

(2) International represents our businesses outside the UK

(3) DACH - Germany, Austria and Switzerland

(4) EMEA excl DACH - UK, Ireland, Belgium, Netherlands, Luxembourg, France, Spain and Dubai

(5) ROW - All other countries we operate in excluding Germany, Netherlands, UK, USA and Japan

(6) Engineering now includes Energy, which was previously reported separately. Up-stream oil and gas comprises approximately 5% of the new Engineering sector

(7) The contractor order book represents value of net fees until contractual end dates, assuming all contractual hours are worked

(8) The Netherlands temporary technical sector market turnover (ABU Data 2020) and Global Staffing Industry Analysts ("SIA") data August 2020 update and USA SIA September 2020 update

 

- Ends -

 

 Enquiries:

 

 

 

 SThree plc

020 7268 6000

 Mark Dorman, Chief Executive Officer

 

 Alex Smith, Chief Financial Officer

 

 Steve Hornbuckle, Company Secretary

 

 

 Alma PR

020 3405 0205

 

 Rebecca Sanders-Hewett

 Susie Hudson

 

SThree@almapr.co.uk

 

 

Notes to editors

 

SThree plc brings skilled people together to build the future. It is the only global pure-play specialist staffing business focused on roles in Science, Technology, Engineering and Mathematics ('STEM'), providing permanent and flexible contract talent to a diverse base of over 9,000 clients in 15 countries.

 

The Group's c.2,600 staff cover the Technology, Life Sciences, Engineering and Banking & Finance sectors.

 

SThree plc is quoted on the Premium Segment of the Official List of the Financial Conduct Authority under the ticker symbol STEM and also has a US level one ADR facility, symbol SERTY.

 

Important notice

 

Certain statements in this announcement are forward looking statements. By their nature, forward looking statements involve a number of risks, uncertainties or assumptions that could cause actual results or events to differ materially from those expressed or implied by those statements. Forward looking statements regarding past trends or activities should not be taken as representation that such trends or activities will continue in the future. Certain data from the announcement is sourced from unaudited internal management information and is before any exceptional items. Accordingly, undue reliance should not be placed on forward looking statements.


ISIN:GB00B0KM9T71
Category Code:TST
TIDM:STEM
LEI Code:2138003NEBX5VRP3EX50
Sequence No.:89597
EQS News ID:1154782
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
3rd Jun 20249:50 amRNSTotal Voting Rights
13th May 20244:00 pmRNSDirector/PDMR Shareholding
25th Apr 202411:44 amRNSResult of AGM
15th Apr 20243:48 pmRNSDirector/PDMR Shareholding
10th Apr 202412:14 pmRNSChange of Auditor
2nd Apr 202412:10 pmRNSDirectorate Change
22nd Mar 20244:29 pmRNSDirector/PDMR Shareholding
19th Mar 20243:30 pmRNSDirector/PDMR Shareholding
19th Mar 20247:00 amRNSFY24 Q1 Trading Update
14th Mar 202412:11 pmRNSDirector/PDMR Shareholding
12th Mar 20243:59 pmRNSDirector/PDMR Shareholding
7th Mar 20249:20 amRNSDirector/PDMR Shareholding
4th Mar 202410:54 amRNSAnnual Financial Report
23rd Feb 20242:00 pmRNSBlock listing Interim Review
13th Feb 20244:45 pmRNSDirector/PDMR Shareholding
1st Feb 202410:20 amRNSTotal Voting Rights
30th Jan 20247:00 amRNSFY23 Final Results
23rd Jan 20244:25 pmRNSChange of Registrar
15th Jan 20241:19 pmRNSDirector/PDMR Shareholding
18th Dec 20234:56 pmRNSDirector/PDMR Shareholding
14th Dec 202310:58 amRNSDirector/PDMR Shareholding
14th Dec 20237:00 amRNSFY23 Full Year Trading Update
8th Dec 20234:30 pmRNSDirectorate Change
1st Dec 20232:27 pmRNSTotal Voting Rights
23rd Nov 20237:00 amRNSAppointment of Joint Corporate Brokers
16th Nov 202312:41 pmRNSDirector/PDMR Shareholding
14th Nov 20239:45 amRNSHolding(s) in Company
2nd Nov 20232:45 pmRNSTotal Voting Rights
16th Oct 20232:02 pmRNSDirector/PDMR Shareholding
2nd Oct 20233:53 pmRNSTotal Voting Rights
20th Sep 20231:19 pmRNSDirector/PDMR Shareholding
19th Sep 20237:00 amRNSFY23 Q3 Trading Update
13th Sep 202310:35 amRNSDirector/PDMR Shareholding
1st Sep 202312:17 pmRNSTotal Voting Rights
23rd Aug 202311:40 amRNSBlock listing Interim Review
16th Aug 20232:16 pmRNSDirector/PDMR Shareholding
15th Aug 20231:26 pmRNSHolding(s) in Company
1st Aug 20234:30 pmRNSTotal Voting Rights
25th Jul 20237:00 amRNSRESULTS FOR THE SIX MONTHS ENDED 31 MAY 2023
13th Jul 20234:43 pmRNSDirector/PDMR Shareholding
6th Jul 20235:10 pmRNSHolding(s) in Company
3rd Jul 202310:42 amRNSTotal Voting Rights
20th Jun 20234:53 pmRNSDirector/PDMR Shareholding
20th Jun 20237:00 amRNSFY23 Half Year Trading Update
13th Jun 202311:37 amRNSDirector/PDMR Shareholding
1st Jun 20233:49 pmRNSTotal Voting Rights
15th May 202311:48 amEQSSThree: DSH-Director/PDMR Shareholding*
2nd May 202310:13 amEQSSThree: TVR-Total Voting Rights
19th Apr 20233:41 pmEQSSThree: AGM-AGM Statement
18th Apr 20239:46 amEQSSThree: DSH-Director/PDMR Shareholding*

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.